21世纪经济报道记者陈思琦深圳报道 从增速看，除龙岗、宝安暂未公布数据，南山、福田、龙华、光明、坪山、深汕6区跑赢全市。其中，坪山(10.5%)、深汕(10.3%)实现两位数迅猛增长，正 围绕车、药等特定的高附加值方向，谋求产业结构优化升级。 | | 深圳各区2025年经济数据 | | | --- | --- | --- | | 城区 | GDP（亿元） | 増速 | | 南山区 | 10102.38 | 6.3% | | 福田区 | 6420.22 | 8% | | 龙岗区 | 预计破6000 | 未公布 | | 宝安区 | 未公布 | 未公布 | | 龙华区 | 3311.13 | 6.1% | | 罗湖区 | 2535.26 | 4.2% | | 光明区 | 1841.76 | 6.5% | | 坪山区 | 1602.89 | 10.5% | | 哉田区 | 未公布 | 5% | | 大鹏新区 | 487.39 | 4.3% | | 深汕特别合作区 | 252.12 | 10.3% | | 深圳全市 | 38731.8 | G-5.5% FINE | | | 数据来源：深圳市及各区统计局、各区政府工作报 ...

As we move through the first quarter of 2026, I am optimistic about Neurocrine Biosciences ( NBIX ) because they have been able to demonstrate the success of their business development strategy in 2025. They were ableI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is a mix of fundamental analysis and future trend pred ...

Core Insights - Neurocrine Biosciences (NBIX) has successfully demonstrated its business development strategy in 2025, leading to optimism for the company as it enters the first quarter of 2026 [1] Company Performance - The company is positioned in high-growth sectors that are expected to experience exponential expansion [1] - There is a strong focus on disruptive technologies and forward-thinking enterprises, indicating a commitment to innovation [1] Investment Strategy - The approach taken by the company combines fundamental analysis with future trend predictions, aiming to leverage innovation for substantial returns [1]

（睿智医药公众号） 此次合作将开启AI从辅助工具向核心基础设施演进的新阶段，系统推动药物研发质效跨越，合力打造成为创新药研发 领域AI自动化的标杆项目。 近日，睿智医药与镁伽科技正式签署战略合作。双方将以"构建智能生物制造生态，引领行业变革"为目标，结合镁伽 AI-Agent全场景闭环的技术能力，以及睿智医药先进的临床前研发能力与积累的高质量数据资产，共建可进化、可部 署的"AI驱动的生物医药自动化实验室"。 ...

Financial Performance - HBC recorded total operating revenues of NOK 72.2 million in Q4 2025, an increase from NOK 64.9 million in Q4 2024. Full year 2025 total operating revenues amounted to NOK 256.3 million compared to NOK 265.5 million in 2024 [1] - EBITDA for Q4 2025 was negative NOK 26.5 million, slightly worse than negative NOK 26.1 million in Q4 2024. For the full year 2025, EBITDA was negative NOK 72.9 million compared to negative NOK 65.3 million in 2024 [2] - Cash and cash equivalents increased by NOK 1.6 million during Q4 2025, ending at NOK 67.1 million as of December 31, 2025, with total liquidity reaching NOK 77.5 million [3] Product and Market Development - Human Nutrition B2B revenues increased by 300% year-on-year, driven by strong demand for ProGo® and CalGo®, along with a solid sales start for NT-II™ [6] - Expanded regulatory access achieved with ingredient approvals in Australia and South Korea, facilitating entry into large VMS and functional food markets [6] - Pet Nutrition B2B volumes and revenues improved, supported by increased customer engagement and trade-show activity [6] Research and Development - Significant R&D milestones achieved during Q4, including peer-review publication of the CalGo® bone health study and IRB approval for a clinical NT-II™ joint health study [6] - HBC has identified unique health benefits through scientific evidence, leading to important academic partnerships and the granting of several patents [5] Corporate Actions - HBC raised NOK 158 million in a private placement and sold a stake in AecorBio Inc. for USD 5 million during Q4, with transactions expected to finalize in Q1 2026 to support growth and R&D [6] - HBC spun out a biotech-focused company, HBC Immunology (HBCI), which has raised external finance for its lead program in prostate cancer [7]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - A class action lawsuit has been initiated against uniQure N.V. for alleged securities fraud, with a focus on misrepresentations regarding the company's drug candidate and regulatory approvals [1] Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1] - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [1] Group 2: Legal Representation - Rosen Law Firm, known for its success in securities class actions, is leading the lawsuit and encourages investors to select qualified counsel [1] - The firm has a strong track record, having achieved significant settlements for investors, including over $438 million in 2019 [1] - Investors can join the class action by contacting Rosen Law Firm through their website or phone [1] Group 3: Implications for Investors - The lawsuit alleges that when the true details about uniQure's business and operations were revealed, investors suffered damages [1] - A lead plaintiff is needed to represent the class, and interested parties must move the Court by April 13, 2026 [1] - Until the class is certified, investors are not represented by counsel unless they retain one [1]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for securities law violations, specifically for making false and misleading statements regarding its FDA approval process and study design [1] Group 1: Lawsuit Details - The lawsuit pertains to violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is from September 24, 2025, to October 31, 2025, with a deadline for lead plaintiff appointments set for April 13, 2026 [1] - The complaint alleges that uniQure's public statements were materially misleading, particularly regarding the likelihood of delays in its Biologics License Application (BLA) with the FDA due to the need for additional studies [1] Group 2: Company Background - uniQure N.V. is a biotechnology company that focuses on gene therapies [1] - The company is listed on NASDAQ under the ticker symbol QURE [1] - The DJS Law Group, which is handling the lawsuit, specializes in securities class actions and corporate governance litigation [1]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. for the period between September 24, 2025, and October 31, 2025, due to alleged misrepresentations regarding the company's drug candidate and its regulatory approval status [1]. Group 1: Lawsuit Details - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline, which led to investors suffering damages when the true information became public [5]. - Investors who purchased uniQure shares during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information. A lead plaintiff must file a motion by April 13, 2026 [3][6]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7].

Good afternoon, and welcome to the HotCopper HotList column. Every week, ASX companies of every shape and size go through the ups and downs that is the Australian trading rollercoaster. Fortunes made, and equity lost each time the bourse opens – which is why watching market trends is so key.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.You certainily don’t have to go it alone, though: We’ve put togethe ...